Replies to post #7026 on 123Tom's TA study group

[123tom]

You asked a good question in the AVXL forum. I'm interested in the answer as well.
Why did they reduce dosage?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145418373

but it sounds like the financials are ok. Are you encouraged about the financials? or neutral? does it make AVXL a little "safer" looking ?
In terms of how it might relate to price action, a positive outlook in financials might make me think 2 dollars will hold as a bottom. something more negative in the financials might make me anticipate lower target bottoms like 1.80 again.

[Doc328]

I think there's been a little dilution but not enough to explain the drop in share price.

From yesterday's 10K, shares 12/12/2018 are 46,586,162 and shares EOY 9/30/2018 were 45,933,472.

From 8/9/2018 10Q, shares that day were 45,431,305 and shares EOQ 6/30/2018 were 45,212,074.

Cash and cash equivalents dropped 3M (25.8 to 22.9M) from 6/30 to 9/30

Of course at this point there are probably just a small number of patients in the two active studies so there have been very few payments to the sites. Expenses are about to increase.

Some studies have paid us monthly (with about a 30-60 day delay from actual visit/service) and others have paid us quarterly (so could be 30-120 days from date of visit). Payments are first made to the CRO and then to the sites (with of course a large cut kept by the CRO for their services/profit)